EP300 and pancreatic neoplasm: Moreover, pancreatic cancer with KDM6A loss shows vulnerability to histone deacetylase (HDAC) inhibitor as KDM6A cooperates with histone acetyltransferase p300 (EP300) to regulate gene expression, and HDACi treatment reactivates p21 (CDKN1A) expression to restore cell cycle regulation in KDM6A-deficient pancreatic cancer in vitro [49].